EUVIMEDEUVIMED entdecken
Leserbrief

Efficacy of Induction Therapy With Calcineurin Inhibitors in Combination With Ustekinumab for Acute Severe Ulcerative Colitis

Pauline Veyrard, Gauthier Pellet, David Laharie, Maria Nachury, Pascal Juillerat, Xavier Roblin

Clinical Gastroenterology and Hepatology · 2023-05 · 21 (5) · 1354-1355.e2

DOI: 10.1016/j.cgh.2022.03.008 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Clinical Gastroenterology and Hepatology, 2023-05. Verfasst von Pauline Veyrard und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, CHU Saint-Etienne, Clinique Mutualiste, Saint Etienne, France. Hauptthemen laut MEDLINE: Colitis, Ulcerative. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 7 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ulcerative colitis is a chronic inflammatory bowel disease. Approximately 20% of patients experience an acute severe attack during their life. In acute severe ulcerative colitis (ASUC), first-line therapy is intravenous (IV) steroids. In the absence of clinical improvement, 2 medical options can be considered: ciclosporin or infliximab.1 In ASUC, ciclosporin is commonly used as a bridging therapy for thiopurines. Pellet et al2 found that the same bridge strategy with vedolizumab was effective and can avoid colectomy. Given that an increasing number of patients with ASUC have been exposed to thiopurines, vedolizumab, and anti-tumor necrosis factor biologic therapies, newer approaches are needed in these patients, such as tofacitinib or ustekinumab. Ustekinumab, an antagonist of the p40 subunit of interleukin-12 and interleukin-23, has shown efficacy in ulcerative colitis and can be given in this indication.3 In this retrospective study, we evaluate the efficacy and safety of a bridge from calcineurin inhibitor to ustekinumab in patients with ASUC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeHumansCalcineurin InhibitorsUstekinumabCyclosporineInduction ChemotherapyRetrospective StudiesTreatment OutcomeInfliximabImmunologic Factors

Substanzen

Calcineurin InhibitorsUstekinumabCyclosporineInfliximabImmunologic Factors

Autor:innen und Institutionen

  • Department of Gastroenterology, CHU Saint-Etienne, Clinique Mutualiste, Saint Etienne, France.
  • Department of Gastroenterology and Hepatology, Centre Médico-chirurgical Magellan Hôpital Haut-Lévêque, CHU de Bordeaux, Université de Bordeaux, INSERM CIC 1401, Bordeaux, France.
  • Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE, Institute for Translational Research in Inflammation, Lille, France.
  • Clinic for Visceral Surgery and Medicine Inselspital, Bern University Hospital, Bern, Switzerland.
  • Department of Gastroenterology, CHU Saint-Etienne, Saint-Etienne, France.

Zitieren

APA

Veyrard, P., Pellet, G., Laharie, D., Nachury, M., Juillerat, P., & Roblin, X. (2023). Efficacy of Induction Therapy With Calcineurin Inhibitors in Combination With Ustekinumab for Acute Severe Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 21(5), 1354-1355.e2. https://doi.org/10.1016/j.cgh.2022.03.008

Vancouver

Veyrard P, Pellet G, Laharie D, Nachury M, Juillerat P, Roblin X. Efficacy of Induction Therapy With Calcineurin Inhibitors in Combination With Ustekinumab for Acute Severe Ulcerative Colitis. Clinical Gastroenterology and Hepatology. 2023;21(5):1354-1355.e2. doi:10.1016/j.cgh.2022.03.008

BibTeX
@article{Veyrard2023,
  author = {Veyrard, Pauline and Pellet, Gauthier and Laharie, David and Nachury, Maria and Juillerat, Pascal and Roblin, Xavier},
  title = {Efficacy of Induction Therapy With Calcineurin Inhibitors in Combination With Ustekinumab for Acute Severe Ulcerative Colitis},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2023},
  volume = {21},
  number = {5},
  pages = {1354--1355.e2},
  doi = {10.1016/j.cgh.2022.03.008}
}
Kostenlos starten →